Shares of Afya Limited (NASDAQ:AFYA – Get Free Report) have received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $17.10.
AFYA has been the subject of several research reports. Zacks Research downgraded shares of Afya from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. reduced their price target on Afya from $21.50 to $21.00 and set a “neutral” rating on the stock in a research report on Monday, June 22nd. Bank of America reaffirmed a “neutral” rating on shares of Afya in a report on Thursday, June 11th. Weiss Ratings restated a “hold (c)” rating on shares of Afya in a research report on Monday, April 20th. Finally, Wall Street Zen lowered shares of Afya from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd.
Check Out Our Latest Analysis on Afya
Afya Stock Performance
Insider Activity at Afya
In other news, VP Lelio De Souza Junior sold 36,204 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $15.00, for a total transaction of $543,060.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Gomiero Mirella Basolli sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $14.80, for a total value of $148,000.00. Following the completion of the sale, the vice president owned 34,530 shares of the company’s stock, valued at $511,044. The trade was a 22.46% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,745 shares of company stock worth $1,314,175. Insiders own 0.80% of the company’s stock.
Institutional Investors Weigh In On Afya
Hedge funds and other institutional investors have recently modified their holdings of the stock. Doma Perpetual Capital Management LLC grew its holdings in Afya by 50.6% during the 3rd quarter. Doma Perpetual Capital Management LLC now owns 891,639 shares of the company’s stock valued at $13,910,000 after buying an additional 299,419 shares in the last quarter. Swedbank AB raised its holdings in shares of Afya by 170.3% in the 4th quarter. Swedbank AB now owns 189,200 shares of the company’s stock valued at $2,916,000 after purchasing an additional 119,200 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Afya during the 2nd quarter worth $731,000. Qube Research & Technologies Ltd acquired a new stake in Afya in the third quarter valued at approximately $610,000. Finally, Pictet Asset Management Holding SA purchased a new stake in shares of Afya during the fourth quarter worth about $508,000. 88.02% of the stock is currently owned by hedge funds and other institutional investors.
About Afya
Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.
At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.
Featured Stories
- Five stocks we like better than Afya
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
